|
NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²Ñо¿NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²Ñо¿
̨±£¾ü¶ÅÃñȨ½ºº»ÆÞ±¹ùò« (Î人´óѧ¿ÚǻҽѧԺУ·À¿Æºþ±±Î人430079)
[ÕªÒª]Ä¿µÄ£»ÆÀ¼ÛNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¿¹ÑÀ¾ú°ßºÍÑÀö¸Ñ×µÄÁÙ´²¹¦Ð§¡£·½·¨×ñÕÕËæ»ú¡¢Ë«ÓС¢¶ÔÕÕµÄÊÔÑéÔÔò£¬°´ÄÉÈëºÍÅųý±ê×¼½«100ÃûÄêÁäÔÚ2o¡«48ËêµÄÊÜÊÔÕßËæ»ú·Ö³ÉÊÔÑé×é(ʹÓÃNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à)ºÍ¿Õ°×¶ÔÕÕ×é(ʹÓÃͬһ¹«Ë¾Éú²úµÄÆÕͨÑÀ¸à)£¬²ÉÓÃÎ÷°ßÖ¸ÊýºÍÑÀö¸³öѪָÊýÆÀ¼ÛÊÜÊÔÕßµÄÑÀö¸½¡¿µ ×´¿ö¡£½á¹û£ºÊÔÑé×é¾ú°ßÖ¸ÊýºÍÑÀö¸³öѪָÊýÓëÊÔÑéǰÏà±ÈÔÚͳ¼ÆÑ§ÉÏÓÐÏÔÖøÐÔ²îÒ죬ÊÔÑé6ÖܺóÑÀö¸³öѪָÊýºÍ¾ú°ßÖ¸Êý·Ö±ð½µµÍÁË58.8%ºÍ16.4ïöø¶ÔÕÕ×é¾ú°ßÖ¸ÊýºÍÑÀö¸³öѪָÊýÔÚͳ¼ÆÑ§ÉÏÎÞÏÔÖøÐÔ²îÒì(P¡µo.o5)¡£½áÂÛ±¾Ñо¿ÌáʾNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÄÜͨ¹ý¼õÉÙ¸úÉϾú°ßºÍ¼õÇáÑÀö¸³öѪ¶øÏÔÖø¸ÄÉÆÑÀö¸½¡¿µ×´¿ö¡£ ¹Ø¼ü´Ê1ÉúÎï»îÐÔ²£Á§Àë×Ó¿¹¾ú°ß¿¹ÑÀö¸Ñ×ÑÀ¸à [ÖÐͼ·ÖÀàºÅ]R780 1[ÎÄÏ×±êʶÂë]A[ÎÄÕ±àºÅ¡¿1671Ò»-7651(2005)06-0661--03
clinical study of Dentifrice contai ning NovaMin B ioacti vc Glass pa rticle on Anti-plaquelA nti-Gingivi tis. TA/ Bat?-j_DLF. ¡¤ Mrn-qualr. Jr. 410 Ahn, rial.. *hool afjlolnaraAngy, tF ¡¤ uAan taHir ¡¤ ersjjv, ITh)}ai? 4. 1079 [Abstract]objectives The anti-plaque / anti-gingivitis pffiracy was evaluated clinically nrl a dpntifrice containing No2 vaMin Bi oactive Glass ( test) compared with dentifrice wi\hmJt Bi oartive class ( contr ol) over 6-week peri od. Methods The studv design was a randomized, dnuhlp-6linoe4, ( ¡¤ (mtr oiled clinical trial. 1 o0 subjectswith age ranging fr om 20 Io 48 were randomly divided int o t wo gr oup s. thr test gr oup and \he contr ol gr oup. The Planue I ndex ( PL I ) and Cingiva1Ble € 82 ing Index (CB I ) were deter mined at the baseline and 6 weeks later. Results The Gingival Blpeding l nd€x (GB I) and plaque Index ( pL lj were significantly reduced in the test gr ottp ( n-47) by 58. 8% and 16. 4%, res pectrvely, while there was no difference of the C B I and pL I for the rontr ol gr o11p (.-48). Conclusion This study demonstrated that the dentifrice containing Bi oactive Glass significantly I nip roved oral hralth asmeasurpd hy a rrduction in gingival bltaeding and a reduct I on in supra-gingi va] p laque comparpd wi\h a free dentifrice over 6-week period. [ Keyw ord¡ì] Bioactive Class Anti-gingivitis Anti-plaque Dentifrice
Nova MinÑÀ¸àÊÇÒ»ÖÖºÏÉúÎï»îÐÔ²£Á§Àë×ÓµÄÑÀ¸à£¬¸Ã²ÄÁÏÓɶàÖÖÎÞ»úÀë×Ó×é³É£¬°üÀ¨¹è¸Æ¡¢ÄƺÍÁ׵ȣ¬Ëü¾ßÓÐÒÖÖÆ¿ÚÇ»ÖÂȣϸ¾úºÍÑÀÖÜÏà¹ØÏ¸¾ú¼°¿¹ÑÀ±¾ÖʹýÃôµÄ×÷ÓÃl'"41¡£±¾Ñо¿µÄÄ¿µÄÊÇͨ¹ýΪÆÚ6ÖܵÄÁÙ´²ÊÔÑ飬ÆÀ¼ÛNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¶Ô¿ØÖÆÑÀ¾ú°ßºÍ¼õÇáÑÀö¸³öѪµÄÁÙ´²¹¦Ð§£¬Ñ°ÕÒÒ»ÖÖά»¤ÑÀö¸½¡¿µÇÒ°²È«ÓÐЧµÄÄÚÎÒ±£½¡ÓÃÆ·¡£
²ÄÁÏÓë·½·¨ 1.1²¡ÀýÑ¡ÔñÔÚÁÙ´²ÊÔÑ鿪ʼǰ£¬ÏòÔ¸Õß¾ùÇ©ÊðÖªÇéͬÒâÊé²¢Ìṩҽѧ²¡Ê·¡£Î人´óѧµÀµÂÂ×ÀíίԱ»áÉóºË²¢Í¬ÒâÁ˱¾ÊÔÑé²Ý°¸¡£°´ÄÉÈëºÍÅųý±ê×¼¶Ô×ÔÔ¸Õß½øÐÐɸѡÒÔÈ·¶¨Ñù±¾ÈËȺ¡£ÄÉÈë±ê×¼ÄêÁäÔÚ18ËêÒÔÉÏÉíÌ彡¿µÓÐÈÕ³£Ë¢ÑÀϰ¹ßÖÁÉÙ2o°åÑÀµÄ¼ÕºóÃæ¿ÉÒԼǼÐÔ±ð²»ÏÞ¡£Åųý±ê×¼£ºÓÐϵͳÐÔ¼²²¡Ðпª·ÅÐÔÈ£¡£ÑÀËèÑס£ÑÀÖÜÑ×»¼Õß¹ÚÇźÍÕý»û»¼ÕßÈÑÉïÆÚºÍ²¸Èé}W¶ÔÑÀ¸à¹ýÃô¼°ÆäËû¿ÚÇ»ÎÀÉú²úÆ·¹ýÃôÕß³¤ÆÚʹ´¨¿¹ÉúËØÖÎÁÆÕß¡£ 1.2ÊÔÑé·Ö×éÊÔÑé×ñÕÕËæ»ú¡¢Ë«°Ù¡¢¶ÔÕÕÔÔò½øÐС£½«·ûºÏÌõ¼þµÄ100ÃûÊÜÊÔÐа´¼ÆËã»úÉú³ÉµÄËæ»úÊý×Ö½øÐзÖ×飬ÊÔÑé×é50ÃûʹÓÃNovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à£¬¶ÔÕÕÈ«ft 50ÃûʹÓÃͬһ¹«Ë¾Éú²úµÄ²»º¬NovaMinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¡£ 1.3ÊÔÑé·½·¨ÊÜÊÔÕßʹÓÃÉÏÊöÑÀ¸àÔçÍí¸÷Ë¢ÑÀ1´Î£¬ÑÀ¸à±ØÐë²¼ÂúÕû¸öˢ룬ÿ´Îlm in¡£ÊÔÑé°üÀ¨3´Î¿ÚÇ»¼ì²éºÍ¾ú°ßÖ¸Êý(sihress&L6e plaq¡¤eindex, Pl. D 151. ÑÀö¸ lli Ѫָ Êý ( gingival Irleeding in2dex,CBD161µÄÆÀ¼Û(ɸѡ0ÖÜʱ»ùÏ߯À¹ÀºÍ6ÖÜʱµÄÄ©ÆÚÆÀ¹À)¡£ÔÚ»ùÏßÑÀÖÜÆÀ¼Ûºó¶ÔËùÓÐÊÜÊÔÕß½øÐÐö¸ÉÏÇåÖΡ£ÔÚ»ùÏ߯À¼ÛºÍ×îºóÆÀ¼Ûǰ8 h²»½øÐпÚÇ»Çå½à£¬Ñо¿ÆÚ¼ä²»Ê¹ÓÃÆäËû¿ÚÇ»ÎÀÉú´ëÊ©¡£ 1.4¼ì²é±ê×¼Óë·½·¨ËùÓмì²é¾ùÔÚÁÙ´²ÕïÊÒ½øÐУ¬Ê¹Óÿھµ°Ú×ÓºÍÑÀÖÜ̽Õë¶ÔÊÜÊÔÕß½øÐпÚÇ»¼ì²é¡£Ê×ÏȶÔÊÜÊÔÆÎ½øÐÐÑÀ¾ú°ßȾɫ£¬·½·¨Ã¿ÈËš°´Î5µÎȾɫ¼Á£¬Öö¸ÀÊÜÊÔÕߺ¬Êþ15¡¢£¬Ê¹È¾É«¼Á³ä·ÖÓëÑÀÃæ½Ó´¥£¬ÇåË®Êþn£¬È»ºó²ÉÓÃpI.IºÍGBIÆÀ¼Ûö¸ÉϾú°ßºÍÑÀö¸³öѪÇé¿ö¡£Ã¿´ÎÑÀÖܼì²éµÄͬʱҲ¼ì²éÃÅÇ»´½¡¢¼Õ¡¢ÉàµÈÈí×éÖ¯Çé¿ö´¨ÒÔÆÀ¼Û¸ÃÑÀ¸à¶Ô¿ÚÇ»Èí×éÖ¯µÄ¿ÉÄܸ±×÷Óᣠ1.5Êý¾Ý´¦ÀíËùÓеÄÊý¾ÝÊäÈë¼ÆËã»ú£¬²ÉÓÃSP5510.ÃÅÈí¼þ½øÐÐͳ¼Æ·ÖÐá£ÓöÀÁ¢Ñù±¾µÄt¼ìÑé·ÖÎöÆÀ¼ÛʹÓÃÑÀ¸à6ÖܺóPLIºÍGBIµÄÇé¿ö¡£ 2½á¹û 2.1ÊÜÊÔÕß»ù±¾Çé¿ö95ÃûÑù±¾Íê³ÉÁË×îºóµÄÊÔÑé¡£5¸öÑù±¾ÒòΪÓëÊÔÑéÑÀ¸àµÄÎ޹صÄÔÒò£¬Ã»ÓÐ×îÖÕÍê³ÉÊÔÑé¡£ÊÔÑé¹ý³ÌÖÐûÓи±×÷Óõı¨¸æ¡£ÊÜÊÔÕß»ù±¾Çé¿ö¼û±í1. ±í1ÊÜÊÔÕß»ù±¾Çé¿ö
2.2ÊÔÑéǰºóPLI¸Ä±äÇé¿öÊÔÑéǰÊÔÑé×éºÍ¶ÔÕÕ×éPLIÎÞÏÔÖøÐÔ²îÒì(P ¡·0.05)¡£ÊÔÑé6ÖÜºó£¬ ÊÔÑé×éPLI½µµÍÂÊΪ16_4%£¬ÊÔÑéǰºóPLIÓÐÔÚͳ¼ÆÑ§JÏÔÖøÐÔ²îÒì(p<0.05)¡£¶ÔÕÕ×éÊÔÑéǰºóPLIÎÞÏÔÖø²îÒì(P >0.05)£¬¼û±í2. ±í2.ÊÔÑéǰºóPLI¼Ç·Ö
±í3ÊÔÕûǰºóCBIÖ¸Êý¼Ç·Ö
2.3ÊÔÑéǰºóCBI¸Ä±äÇé¿öÊÔÑéǰÊÔÑé×éºÍ¶ÔÕÕ×éCBIÎÞÏÔÖøÐÔ²îÒì(P ¡·0.05)¡£ÊÔÑé6ÖÜºó£¬ ÊÔÑé×éGBI½µµÍÂÊΪ58.8%£¬ÊÔÑé×éǰºóGBIÓÐÔÚͳ¼ÆÑ§Éϸ߶ÈÏÔÖøÐÔ²îÒì(P ¡´0.001)¡£¶ÔÕÕ×éǰºóGBIÎÞÏÔÖø²îÒì(p>0.o5)£¬¼û±í3. 3ÌÖÂÛ ¾ú°ßµÄÐγɺͻýÀÛÔÚÑÀÖܼ²²¡µÄ·¢Éú·¢Õ¹ÖÐÆð·Ç³£ÖØÒªµÄ×÷Ó㬿ØÖƾú°ß¾Í¿ÉÒÔÔ¤·ÀºÍ¿ØÖÆÑÀÖܼ²²¡¡£µ¥´¿»úе¿ØÖƾú°ßÄÜ×è°ÑÀö¸Ñ×ÒÔ¼°ÑÀÖÜÑ׵ĽøÕ¹µ¨AxFls5oÈÕ±¨µÀ¶ÔÓÚÒÀ´ÓÐÔ²îµÄ»¼¿Í¡¢Æä²¡ÇéÓнøÕ¹»ò¸´·¢µÄÕ÷Ïó£¬Òò´Ë»úеÐÔ¿ØÖƾú°ßÅäºÏÒ©Î↑ʼ½øÈËÈÕ³£Éú»îÒÔÔ¤·ÀÑÀö¸Ñ׵ķ¢Éú£¬ÈçÏ´±ØÌ«ÑÀ¸à¡¢ÈýÂÈÉúÑÀ¸àµÈ£¬ËäÈ»ÕâЩÑÀ¸àÈ¡µÃÁ˽ϺõĿ¹ÑÀö¸Ñ×µÄЧ¹û£¬µ«Í¬Ê±´æÔÚζ¿à»òÕß¿ÉÄܶÔÉíÌåÓк¦µÈ¸±×÷Óᣠ±¾Ñо¿µÄÄ¿µÄÊÇÆÀ¹ÀÒ»ÖÖÐÂÐ͵ÄNo\a MinÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸à¶ÔÆÕͨÈËȺµÄÑÀö¸½¡¿µµÄÓ°Ïì¡£ÕâÖÖÐÂÑÀ¸àº¬ÓÐ5%µÄÉúÎï»îÐÔ²£Á§Àë×Ó£¬²»º¬Ë®·ÖÒÔ¼°·ú»¯Îï¡£±¾Ñо¿±íÃ÷ÿÌìʹÓÃÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÁ½´Î£¬6Öܺór.BIϽµ58.8%£¬Í¬Ê±pLIÒ²ÏÔÖøÏ½µ16.4¶ß¡£6ÖܺóÊÔÑé×éÓë¶ÔÕÕ×éµÄPLI(p<0.025)ÒÔ¼°GBI(P¡¶0.001)¾ùÓÐÏÔÖøÐÔ²îÒì¡£ ÉúÎï»îÐÔ²£Á§Àë×ÓÓÃÓÚ¹ÇÔÙÉúÊÖÊõÒÑÓÐ15Äê×î½üµÄÑо¿±íÃ÷ÕâÀà²ÄÁϾßÓÐÄÚÔڵĿ¹¾úÌØÐÔ¡£stoorµÈ½«ÓÐÑÀö¸Ñ×¼°ÑÀÖÜÑ×µÄÓÎÀë×éÖ¯±©Â¶ÓÚÉúÎï»îÐÔ²£Á§Àë×ÓÖÐ10 m inºó£¬°é·ÅÏß·ÅÏ߸˾úÊýÁ¿Ï½µ£¬60 nl inºóÓÎÀë×é֯ʧȥ»îÐÔ£¬Í¬Ê±ÑÀö¸ÆÕßøµ¥°û¾ú£¬ÄÎÊÏ·ÅÏß¾ú¼°±äÐÎÁ´Çò¾ú±©Â¶ÓÚÉúÎï»îÐÔ²£Á§Àë×Ó10.i¡¤ºóҲʧȥËùÓеÄÉúÎï»îÐÔ£¬ÁíÍ⣬AÒ²n¡¾'·¢ÏÖ300²·mµ½500 p-mµÄÉúÎï»îÐÔ²£Á§Àë×Ó¶Ô±äÐÎÁ´Çò¾ú¡¢ÑªÁ´Çò¾ú¡¢ÑÀö¸ÆÕßݵ¥°û¾ú¡¢¾ßºËËó¸Ë¾ú¡¢°é·ÅÏß¹ÊÏ߸˾úÒÔ¼°ÖмäÆÕÀ×ÎÖ¾ú¶¼ÓÐÒÖ¾úЧ¹û¡£×÷ÕßÈÏΪÉúÎï»îÐÔ²£Á§Àë×Óɱ¾úÊÇÒòΪÕâÖÖ»îÐÔ²ÄÁÏÄÜÌá¸ßÈÜÒºÖÐpHÖµ£¬»òÕßÊÍ·ÅÁË´óÁ¿µÄ¸ÆÀë×Ó¡£×î½üµÄÑо¿Ò²Ö¤Êµ¼ÓÈËNora\linÉúÎï»îÐÔ²£Á§Àë×ÓµÄÑÀ¸à£¬Äܽµfص±äÐÎÁ´Çò¾ú¡¢¾ßºËËó¸Ë¾ú£¬ÄÎÊÏ·ÅÏß¾ú¡¢ÑªÁ´Çò¾úÅàÑø»ùÖÐÓÎÀëϸ¾úµÄ»îÐÔ¡£¹Å3%ºÍ10WÉÏÎï»îÐÔ²£Á§Àë×ÓµÄI3Ï¡ÊÍÒºÖÐÄܽµµÍ¾ßÒÀËó¸Ë¾úµÄÉúÎï»îÐÔ4.5¸ö¶ÔÊýÖµÏáѪÁ´Çò¾úÔòɥʧÁËÈ«²¿ÉúÎï»îÐÔ. ÓëÆäËü¿¹¾úÒ©ÎïµÄÁÙ´²Ñо¿²»Í¬£¬±¾Ñо¿GBI½µµÍ½ÏPLI¼õÉÙ¸üΪÃ÷ÏÔ¡£EberharclµÈ"Ò²±¨µÀÁËÓÃÉúÎï»îÐÔ²£Á§Àë×Ó½¬½øÐÐÊÔÑéÐÔÑÀö¸Ñ×µÄÁÙ´²Ñо¿£¬Ê¹ÓÃÉúÎï»îÐÔ²£Á§Àë×Óºó²¢Ã»Óз¢ÏÖ΢ÉúÎïˮƽµÄ»îÐÔ½µµÍ£¬µ«ÊÇÑ×Ö¢µÄÁÙ´²Ö¸Õ÷¼õµÍ²¢ÇÒILÒ»1bˮƽϽµ ±¾Ñо¿Ö¤ÊµÁ˺¬ÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÔڽ϶Ìֹʱ¼äÄÚÄÜÏÔÖø½µµÍÑÀö¸Ñ×Ö¢£¬²¢ÔÚʹÓÃÆÚ¼äδ¼ûÈκβ»Á¼·´Ó¦¡¢ÊÇÒ»ÖÖ²»º¬Óп¹ÉúËØ»ò·ú»¯ÎïÈ´¶ÔÑÀö¸½¡¿µÓÐÖÎÁÆÐ§¹ûµÄÑÀ¸à¡£µ«ÊÇ£¬ÐèÒª¸ü½øÒ»²½µÄ³¤ÆÚÁÙ´²Ñо¿ÆÀ¼ÛÕâÖÖÉúÎï»îÐÔ²ÄÁ϶ÔÖÎÁÆÑÀö¸Ñ×µÄÔ¶ÆÚÁÆÐ§£¬ÒÔÑо¿Ö¤Êµ(ãè1µÄ½µµÍÊÇ·ñÓÉÓÚ¾ú°ß×é³ÉµÄ¸Ä±äÈçÊýÁ¿µÄ¼õÉÙ»ò¾úÖֵı仯£¬»¹Êǽö½ö¾ú°ß×ÜÊýµÄϽµ¡£ ×ÜÖ®£¬±¾Ñо¿ÌáʾNnviM inÉúÎï»îÐÔ²£Á§Àë×ÓÑÀ¸àÄÜͨ¹ý¼õÉÙö¸ÉϾú°ß¡¢¼õÇáÑÀö¸³öѪ¶øÏÔÖø¸ÄÉÆÑÀö¸½¡¿µ×´¿ö¡£(¸ÐлÎ人Àû°ÙÉú¿Æ¼¼ÓÐÏÞ¹«Ë¾ÌṩÑÀ¸àºÍÑÀË¢Íê³É±¾ÊÔÑé¡£ ²Î¿¼ÎÄÏ×
[ 1Stoor P. Kirstila V, Soderling E, et al. Interactions bel wren bio2active glass 553P4 and periodontal pathogens [ J ]. Microb EcolHpalth Dis. 1996, 9 109-1 14 [ 2Allan 1, Xewman H. Wils onM. Antibacterial activity of parlicu2late Bilgtasa against sup ra-and suhgingival bacteria [ J ]. Bio2malprials. 2001. 22 1 683-1 687
[ 3 ] Lovelace T B. Mell onig JT, Mpffert RM. et al. Clinical evalua2lion of bioar\ive glass in the trpalmenl of prriodontal osseolls tle2feels in humans [ J ]. J Prriodontol, 1998. 69 1 027-! 035
[4]¶ÅÃñȨ£¬ºÏ±£¾ü£¬½ºº£¬µÈ¡£º¬NovÄ¿mlnÉúÎï»îÐÔ²ÄÁϵÄÑÀ¸à¿¹ÑÀ±¾ÖʹýÃôµÄÁÙ´²ÊÔÑ飬¿ÚǻҽѧÑо¿2004,20(6)641-643 [5]1 Silnps» J. L e H. pprinndotal tlittrn»e in p rrgnanry. II, Corr € la2lion brt wppn oral hygienr and periorlonlal rantlilion IJ 1. ArlaOllonl ol Srand, 1 964. 22 1 2 I-1 35 [ 6 ] Ainamo1. Bay I. Problems and p r upu«als fnr rworcling #ingiviti»and p la¡éiur l J ]. InlprDrnl J. 1975, 25 229-235 [ 7 ] Axelnn on P. Lindhe J. The *ignificanre of maintenance cnrp inthe [rpatmpnl of perindonlal tli»ranp [ J ]. J Clin Pr ri o, 1981, 8281-294
[ 8 ] Sinar P, Snrlprling E, Sal onrn Jl. Anrivartprial rfferta of a bi oar2live ¡élasa paelr on oralmicroorgani« mi [ J ]. Aclaotlnnlal Sr and.1998, 56 161-165 [ 9 ] Allan I. Nrwmnn H. Wils on M. Parlirulale Bi oglaas? rrrlucesthe viability of bacterial biofilms fnrmetl on it» »urface in an in-vitro madri [ J ]. Clin Oral ! mp l. 2002, 1 3 53-58[ 10 ] Ebrrhartl j, Rrimrrs N. Dnmmisc : h H. pl al. Thp tffprt of thr [10]p ical atlministratinn of binartivp glans on inflammatory markrrsnf human pxprrimpnlal gingivilin [ J ]. 8i omalrrial«, 2004, 26 545-1 551 1ÊÕ¸åÈÕÆÚ2005-07-29¡¿(±¾Îıà¼ÍôÓ÷ÖÒ) ÁÙ´²¿ÚǻҽѧÔÓÖ¾ 2000 Vol. 16 N. 4 P. 238-239 ÉúÎï»îÐÔ²£Á§Î¢Á£ÖÎÁÆ¿ÚÇ»À£ÑñÁÆÐ§³õ²½¹Û²ì ¡¾ÕªÒª¡¿Ä¿µÄ¹Û²ìÉúÎï»îÐÔ²£Á§Î¢Á£Ó¦ÓÃÓÚ¸´·¢ÐÔ¿ÚÇ»À£ÑñÖÎÁƵÄÁÆÐ§¡£·½·¨120 Ãû¸´·¢ÐÔ¿ÚÇ»À£Ññ»¼ÕßËæ»ú·ÖΪÁ½×飬¶ÔÕÕ×鲡ÈËÐд«Í³ÖÎÁÆ£¬¶øÊµÑé×鲡ÈËÔÚÀ£Ññ¾Ö²¿Ó¦ ÓÃÉúÎï»îÐÔ²£Á§Î¢Á£Ã¿ÈÕÈý´Î£¬²¢¼Ç¼×ÔÓÃÒ©ÖÁÀ£ÑñÓúºÏµÄʱ¼ä¡£½á¹ûÉúÎï»îÐÔ²£Á§Î¢Á£ ¿ÉÃ÷ÏÔ¼õÇá¿ÚÇ»À£ÑñµÄÌÛÍ´²¢¿ÉʹÀ£ÑñÓúºÏ¼Ó¿ì¡£½áÂÛ³õ²½¹Û²ì±íÃ÷ÉúÎï»îÐÔ²£Á§Î¢Á£¶Ô ¿ÚÇ»À£ÑñµÄÖÎÁÆÓÐÓ¦ÓüÛÖµ¡£ ¡¾¹Ø¼ü´Ê¡¿ÉúÎï»îÐÔ²£Á§ÖÎÁƸ´·¢ÐÔ¿ÚÇ»À£Ññ ¡¾ÖÐͼ·ÖÀàºÅ¡¿R781.5¡¾ÎÄÏ×±êʶÂë¡¿A¡¾ÎÄÕ±àºÅ¡¿1003-1634(2000) 04-0238-02 The primary clinical observation of the bioglass particulate used in the treatment of RAU
¾¿¨·½¼ìÑ飬p<0.01,Á½×éЧ¹ûÓзdz£ÏÔÖø²îÒì ÌÖÂÛ ×÷Õßµ¥Î»ÕÅѧ)-(265200ÑĮ̀£¬ÑĮ̀ÊÐÀ³ÑôÖÐÐÄÒ½Ôº) ²Î¿¼ÎÄÏ×
|
¹ºÂò²úÆ·ÔÚÉÌÆ·Ò³µã»÷½øÈëÆì½¢µê¹ºÂò,Äú»¹¿ÉÒÔÔÚÌìèºÍ¾©¶«ËÑË÷¡°°ÂÀÖVÆì½¢µê¡±»òÖµç400-700-2499×Éѯ¹ºÂò